GlobeNewswire: Cue Health Inc. Contains the last 10 of 7 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T14:08:01ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2020/11/19/2130043/0/en/Cue-s-Molecular-Point-of-Care-COVID-19-Tests-Deployed-to-Five-States-in-HHS-and-DOD-Pilot-Program.html?f=22&fvtc=4&fvtv=49085Cue’s Molecular, Point-of-Care COVID-19 Tests Deployed to Five States in HHS and DOD Pilot Program2020-11-19T13:00:00Z<![CDATA[SAN DIEGO, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Cue Health Inc. (Cue) announced today that, as of November 9, the U.S. Department of Health and Human Services (HHS) began deploying its molecular, point-of-care COVID-19 Tests to five states, including Alaska, Florida, Louisiana, New Jersey, and Texas. The tests will be utilized for quick confirmatory testing of positives and suspicious negatives in high-concern populations and congregate care settings, such as nursing homes, long-term care, assisted living facilities, and veterans’ homes. The tests will also be used internally at the Department of Defense (DOD).]]>https://www.globenewswire.com/news-release/2020/06/12/2047409/0/en/Cue-Health-Receives-FDA-Emergency-Use-Authorization-for-Its-Rapid-Portable-Molecular-Point-of-Care-COVID-19-Test.html?f=22&fvtc=4&fvtv=49085Cue Health Receives FDA Emergency Use Authorization for Its Rapid, Portable, Molecular Point-of-Care COVID-19 Test2020-06-12T12:00:00Z<![CDATA[SAN DIEGO, June 12, 2020 (GLOBE NEWSWIRE) -- Cue Health Inc. (“Cue”), a healthcare technology company, announced today that it has received Emergency Use Authorization (“EUA”) from the U.S. Food and Drug Administration (“FDA”) for the company’s rapid, portable, point-of-care COVID-19 test. The Cue COVID-19 Test is a molecular test that detects the RNA of SARS-CoV-2, the virus that causes COVID-19, in 25 minutes using a nasal swab sample taken from the lower part of the nose.]]>https://www.globenewswire.com/news-release/2020/06/10/2046258/0/en/Cue-Health-Closes-100-Million-Series-C-Financing-to-Support-Launch-of-Rapid-Molecular-Testing-Platform.html?f=22&fvtc=4&fvtv=49085Cue Health Closes $100 Million Series C Financing to Support Launch of Rapid Molecular Testing Platform2020-06-10T13:00:00Z<![CDATA[SAN DIEGO, June 10, 2020 (GLOBE NEWSWIRE) -- Cue Health Inc. (“Cue”), a healthcare technology company, announced today the close of its Series C financing round, raising $100 million in new capital.]]>https://www.globenewswire.com/news-release/2020/03/31/2009221/0/en/Cue-Health-Awarded-13-Million-for-Rapid-Portable-Point-of-Care-COVID-19-Test-by-U-S-Department-of-Health-and-Human-Services-Biomedical-Advanced-Research-and-Development-Authority-B.html?f=22&fvtc=4&fvtv=49085Cue Health Awarded $13 Million for Rapid, Portable, Point-of-Care COVID-19 Test by U.S. Department of Health and Human Services Biomedical Advanced Research and Development Authority (“BARDA”)2020-03-31T13:05:06Z<![CDATA[SAN DIEGO, March 31, 2020 (GLOBE NEWSWIRE) -- Cue Health Inc. (“Cue”), a healthcare technology company, announced that is has been awarded a $13 million contract to accelerate the development, validation and FDA clearance of a portable, molecular diagnostic test capable of detecting SARS-CoV-2, the virus that causes COVID-19, in less than 25 minutes using a simple nasal swab. The test is part of the Cue Health Monitoring System, which is designed to be a portable device that can perform a molecular test and connect patients to a mobile health platform that features interventional components such as telemedicine consultations.]]>https://www.globenewswire.com/news-release/2018/07/12/1536562/0/en/Cue-Announces-30-Million-Funding-Contract-from-U-S-Department-of-Health-and-Human-Services-Biomedical-Advanced-Research-and-Development-Authority.html?f=22&fvtc=4&fvtv=49085Cue Announces $30 Million Funding Contract from U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority2018-07-12T13:00:00Z<![CDATA[SAN DIEGO, July 12, 2018 (GLOBE NEWSWIRE) -- Cue Health Inc. (“Cue”), a healthcare technology company, announced today that is has been awarded up to $30 million in base funding and options from the U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (“BARDA”) to accelerate the development and regulatory validation of an over-the-counter and professional use Influenza and Multiplex Respiratory Pathogen diagnostic cartridges for the Cue Health Monitoring System.]]>https://www.globenewswire.com/news-release/2018/07/10/1535447/0/en/Cue-Health-Completes-45MM-Series-B-Financing.html?f=22&fvtc=4&fvtv=49085Cue Health Completes $45MM Series B Financing2018-07-10T14:00:00Z<![CDATA[SAN DIEGO, July 10, 2018 (GLOBE NEWSWIRE) -- Cue Health Inc. (“Cue”), a healthcare technology company developing a range of diagnostic products for professionals and consumers, announced today it has raised over $45MM in Series B financing. The financing will be used to complete development and fund the initial set of FDA 510(k) clinical studies for Cue’s first set of diagnostic products.]]>https://www.globenewswire.com/news-release/2018/07/03/1533132/0/en/Cue-Health-Receives-ISO-13485-Certification.html?f=22&fvtc=4&fvtv=49085Cue Health Receives ISO 13485 Certification2018-07-03T18:01:42Z<![CDATA[SAN DIEGO, July 03, 2018 (GLOBE NEWSWIRE) -- Cue Health Inc. (“Cue”), a healthcare technology company developing a connected diagnostics platform for professionals and consumers, today announced that it received its ISO 13485 certification from British Standards Institution (BSI).]]>